Substance Use Disorder and Family Engagement in Recovery Act
A BILL
To ensure comprehensive wraparound services for families impacted by substance use disorders, and for other purposes.
Sec. 2 Ensuring care and no undue family separation of families impacted by substance use disorder
“(d) Limitations on toxicology testing to detect substance use
“(1) In general—As a condition of receiving payments under this section, each State—
“(A) shall not require the birthing parent of an infant who is identified as being affected by substance abuse or withdrawal symptoms resulting from prenatal drug exposure or a Fetal Alcohol Spectrum Disorder to undergo toxicology testing to detect substance use unless the parent—
“(i) gives clear and informed consent prior to such testing; and
“(ii) is able to access, if necessary for purposes of giving such consent, interpretation services and reasonable accommodations for disabilities;
“(B) shall ensure that a pregnant or postpartum individual taking a prescription drug, including a prescription drug for the treatment of a substance use disorder, in accordance with the recommendations of the prescribing practitioner, shall not be subject to investigations of child abuse and neglect on the basis that such individual is taking such prescription drug;
“(C) shall ensure that—
“(i) any toxicology testing to detect substance use that is provided to a pregnant or postpartum individual taking a prescription drug, including a prescription drug for the treatment of a substance use disorder, in accordance with the recommendations of the prescribing practitioner is consented to by the pregnant or postpartum individual in accordance with subparagraph (A); and
“(ii) such testing (and the results of such testing) shall not affect the individual's access to care or public assistance and shall not be the sole factor in a family separation determination involving the individual; and
“(D) shall ensure that any health care provider involved in the delivery or care of an infant identified as being affected by substance abuse or withdrawal symptoms resulting from prenatal drug exposure, or a Fetal Alcohol Spectrum Disorder, is not required to notify the child protective services system of the State or any unit of local government of the State of the occurrence of such condition in such infant if such condition is the result of the birthing parent of the infant taking a prescription drug, including a prescription drug for the treatment of a substance use disorder, in accordance with the recommendations of the prescribing practitioner, and such provider has no other reason to suspect that the infant is in imminent danger of abuse or neglect.
“(2) Definition of prescription drug—In this subsection, the term prescription drug means a drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) that is subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)).”
Sec. 3 Ensuring a whole-of-government approach through a Federal interagency task force to support families impacted by substance use disorders
Sec. 4 Increasing access to behavioral health care through community health centers
“(VI) behavioral and mental health and substance use disorder services;”
“(G) $130,000,000,000 for the period of fiscal years 2024 through 2028.
“(f) Environmental justice communities—The Secretary shall ensure that not less than 50 percent of the amounts appropriated under subsection (b)(1) for fiscal year 2024 or any fiscal year thereafter are awarded to entities for use with respect to projects or sites located in or serving communities with significant representation of communities of color, low-income communities, or Tribal and Indigenous communities that experience, or are at risk of experiencing, higher or more adverse human health or environmental effects.
“(g) Prohibition—No amounts made available under this section may be used for any activity that is subject to the reporting requirements set forth in section 203(a) of the Labor-Management Reporting and Disclosure Act of 1959 (29 U.S.C. 433(a)).”
Sec. 5 Improving outcomes for pregnant and postpartum patients with substance use disorder and payments to incentivize care for opioid use disorder
“(G) Improves outcomes for pregnant and postpartum individuals with opioid use disorder.”
“(v) pay a higher per applicable beneficiary per month care management fee for an applicable beneficiary who receives pregnancy or postpartum services from a participant.”
Sec. 6 Increasing access to wraparound services for children from families impacted by substance use disorder
“645B. Children from families impacted by substance use disorder
“(a) Grants
“(1) In general—The Secretary shall make grants, in accordance with paragraph (2), to Head Start and Early Head Start agencies to enable the agencies to provide comprehensive health, educational, nutritional, social, and other services to children in Head Start and Early Head Start programs, respectively, from families impacted by substance use disorder, or referring the children to such services, to assure best outcomes for the health, wellness, and school readiness of the children.
“(2) Formula—The Secretary shall make those grants, to fund the activities described in paragraph (1) for a fiscal year, by—
“(A) using the amount appropriated under subsection (c) for that fiscal year; and
“(B) distributing that amount in accordance with clauses (i) (with respect to additional funding for the comprehensive services described in paragraph (1)) and (ii) of section 640(a)(4)(C).
“(b) Construction—A reference in this subchapter (other than this section) to funds appropriated or provided under this subchapter shall not be considered to include funds appropriated or provided under this section.
“(c) Authorization of appropriations—There is authorized to be appropriated to carry out this section $60,000,000 for fiscal year 2024 and each subsequent fiscal year.”
Sec. 7 Coordinating research of the National Institutes of Health
“404P. Research with respect to co-occurring pregnancy and substance use disorder
“The Director of the National Institutes of Health shall establish a consortium on pregnancy, postpartum recovery, and substance use disorder research to establish research priorities and steward research activities across the national research institutes and national centers to understand and mitigate the harms of substance use disorder for pregnant and postpartum patients and their children.”